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Abstract
The controlled release of nicardipine (NC) was achieved by hybridizing its hydrophilic and hydrophobic cyclodextrin (CDs)
complexes, i.e., those with hydroxypropyl-β-cyclodextrin (HPβCD) and triacetyl-β-cyclodextrin (TAβCD), respectively.
1H-nuclear magnetic resonance (1H-NMR) was performed to examine the interaction between both CDs and NC in solu-
tion. The solid complexes of NC : HPβCD and NC : TAβCD were prepared, in a 1 : 1 molar ratio by the spray-drying
method. Complexation in the solid state was demonstrated by differential scanning calorimetry (DSC) and powder X-ray
diffractometry. In vitro dissolution studies were carried out in simulated gastric (pH 1.2) and intestinal (pH 6.8) fluids,
according to the USP basket method. The 1H-NMR studies provided clear evidence of an interaction between the CDs and
the aromatic rings of NC. The DSC thermograms of the solid complexes showed no endothermic peak due to NC melting
and their diffraction pattern was completely diffuse, which suggested the formation of a novel type solid phase with an
amorphous character. The low dissolution rate of NC, a weak basic drug, in alkaline medium was significantly improved
by complexation with HPβCD. In contrast, the in vitro release of this drug from the NC : TAβCD complexes was markedly
retarded in both dissolution media. An optimal formulation was then designed by the combination, in different molar ratios,
of these two complexes. The release behavior of these preparations was investigated and it was observed that the retarding
effect was dependent on the amount of the NC : TAβCD complex. In addition, the initial release rate became faster as the
molar ratio of the NC : HPβCD complex increased.
Introduction
Hydrophilic CDs derivatives such as methylated, hydroxyal-
kylated and branched CDs are useful to improve the low
solubility, dissolution and bioavailability of poorly water-
soluble drugs [1–3]. On the other hand, hydrophobic CDs
like ethylated and peracylated derivatives have potential as
slow/sustained-release carriers of drugs with short biological
half-lives [4–6]. Thus, the critical combination of inclusion
complexes obtained with these two kinds of CDs derivatives
could be a promising drug delivery system, with a prolonged
therapeutic effect.
In this study, NC was chosen as a model drug, since it is
known that has a short-elimination half-life with significant
fluctuations in plasma drug concentrations. NC bioavailabil-
ity is very limited (15–40%), and like other dihydropyrid-
ine derivatives, its standard formulation undergoes rapid
absorption and extensive biotransformation in the liver [7].
The interaction between NC and HPβCD or TAβCD was
investigated in solution and in solid phase. In addition, the
release behavior of these binary systems, as well the corres-
ponding mixtures in different molar ratio, was evaluated in
acidic (pH 1.2) and alkaline (pH 6.8) media.
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Experimental
Materials
NC, HPβCD (Kleptose HPB, MW∼1300, DS 0.63) and
TAβCD were purchased from Effechem SRL (Italy), Ro-
quette (France) and Sigma-Aldrich (Germany), respectively.
1H-NMR studies
The NC : HPβCD and NC : TAβCD samples were prepared
in D2O and C2D5OD: D2O (50 : 50) mixture, respectively.
The 1H-NMR spectra of the pure components and their
respective mixtures were obtained at 298 K on a Varian
Unity-500 spectrometer using a 5-mm reverse detection
NMR probe. The resonance at 4.8 ppm due to residual
solvents (H2O and HDO) was used as internal reference.
Chemical shits were calculated according to: δ = δ
(complex) − δ (free). The stoichiometry of the NC : CDs
inclusion complexes was provided using the continuous vari-
ation technique (Job’s plot) [8]. For each system, solutions
with different CD or NC molar ratio were prepared, where
the total molar concentration was kept constant, i.e., 5 mM
and 2 mM for the NC : HPβCD and NC : TAβCD system,
respectively. Samples were left overnight for equilibration
before measurement.
A rotational Overhauser enhancement experiment
(ROESY) for detection of intermolecular nuclear Over-
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hauser effects (NOEs) between NC and both CDs, was
acquired for the 1 : 1 molar ratio at 298 K using the same
probe. The ROESY experiments were performed with a
mixing time of 500 ms and 100 ms for the NC : HPβCD and
NC : TAβCD system, respectively.
Preparation of solid complexes
The NC : HPβCD complex was prepared by spray-drying
as previously reported [9]. The NC : TAβCD complex was
also prepared by the spray-drying technique. Equimolar
quantities of NC and CDs were dissolved in ethanol : water
(50 : 50). The resulting mixture was stirred for 24 h at room
temperature and the obtained solution was subsequently
spray-dried (LabPlant SD-05), under the following condi-
tions: air flow rate – 50 m3/h; atomising air pressure – 1.0
Bar; inlet temperature – 160 ◦C, outlet temperature – 85 ◦C;
flow rate of the solution – 400 ml/h. The product was sieved
through a 63–160 µm mesh.
Physical mixtures, in 1 : 1 molar ratio, of plain NC and
CDs, were also prepared for reference.
Characterization of the solid complexes
DSC studies
DSC measurements were performed on a Shimadzu DSC-
50 differential scanning calorimeter. All samples accurately
weighed (1 mg of NC or its equivalent) were placed in sealed
aluminium pans, before being heated under nitrogen flow
(20 ml/min) at a scanning rate of 10 ◦Cmin−1, from 25 ◦C
to 200 ◦C (for the NC : HPβCD system) or to 230 ◦C (for the
NC : TAβCD system).
X-ray diffractometry
The powder X-ray diffraction patterns were recorded using
a Philips X’Pert, model PW3040/00 diffractometer, with Co
as anode material and a graphite monochromator, operated
at a voltage of 40 Kv and a current of 35 mA. The samples
were analyzed in the 2θ angle range of 5–50◦ and the process
parameters were set as: scan step size of 0.025◦ (2θ ), scan
step time of 1.25 s and time of acquisition of 1 h.
Dissolution studies
The dissolution profiles were collected using a Vankel
VK7000 apparatus, according to the USP rotating basket
method. The dissolution media consisted of 1000 ml of
enzyme-free simulated gastric (pH 1.2) and intestinal (pH
6.8) fluids (USPXXIV). Powdered samples (n = 6) contain-
ing 30 mg of NC or its equivalent were used. The stirring
speed was 100 ± 2 rpm and the temperature was main-
tained at 37 ± 0.2 ◦C. At settled time intervals up to 8
hours, the concentration of dissolved drug was automatically
determined by UV spectroscopy at 357 nm.
Results and discussion
1H-NMR studies
The drug : CDs interaction in solution was based on the
modification of the 1H-RMN spectrum of NC upon com-
plexation. The 1H-NMR spectra reporting the protons of
TAβCD, NC, and NC : TAβCD mixture (1 : 1) are presen-
ted in Figure 1. Among the different detected signals, those
corresponding to the F, O, N and M protons and also the
G proton of NC were the most affected (δ = 0.016 ppm)
by the presence of TAβCD. Similarly, in the NC : HPβCD
system (not shown) the F, O, N and M protons and the G
proton of NC experienced a pronounced shift variation, i.e.,
δ = 0.020 and 0.025 ppm, respectively.
The stoichiometry for both complexes was established by
application of the continuous variation method, which fol-
lowed the changes in chemical shifts of the G proton, for the
NC : HPβCD system, and of the F, O, N and M protons for
the NC : TAβCD system (Figure 2). Both plots demonstrated
a 1 : 1 stoichiometry, since the maximum was at rNC = 0.5.
From these results, we could propose the coexistence in
solution of two different complexes with 1 : 1 stoichiometry,
concerning the nitro-phenyl ring and the other phenyl group
of the drug. Similar results have been obtained by other
authors [10]. This assumption was further confirmed by
ROESY experiments (not shown). The ROESY spectra of
complexes showed the existence of intermolecular NOEs
between several phenyl ring protons (F, O, N, M and G) of
NC and the HPβCD protons and also between the drug F, O,
N and M protons and the TABCD protons, specially those
from the acetyl groups.
Characterization of the solid complexes
The complete disappearance of the NC endothermic peak
at ca. 174 ◦C was observed in the NC : HPβCD spray-
dried system (Figure 3). Similarly, the NC : TAβCD com-
plex showed no endothermic peaks, due to the melting
of both components (Figure 4). These results suggest the
formation of an amorphous solid dispersion, the molecular
encapsulation of the drug inside the CD cavity, or both [11].
As shown in Figure 5, the diffractograms of the physical
mixtures were constituted practically by the simple super-
position of each single component, indicating the presence
of NC in the crystalline state. In opposite, the spray-dried
systems displayed somewhat diffuse diffraction patterns, in-
dicating the amorphous nature of NC. The presence of a new
solid phase with lower crystallinity than the drug may be at-
tributed to an interaction between NC and both CDs, where
a possible complexation of NC inside the CDs cavity was
contemplated [12], corroborating the DSC observations.
Dissolution studies
The dissolutions profiles of NC and NC : CDs binary sys-
tems in simulated gastric (pH1.2) and intestinal (pH 6.8)
fluids are presented in Figures 6 and 7, respectively. The
dissolution characteristics of NC, a weak basic drug, were
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Figure 1. 1H-NMR spectra of TAβCD (A), NC (B) and NC : TAβCD (1 : 1) mixture (C).
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Figure 2. Job’s plots corresponding to the chemical shift displacement of the F, O, N, M () and the G () protons of drug for the NC : TAβCD and
NC : HPβCD system, respectively.
Figure 3. DSC thermograms of NC (A), HPβCD (B), NC : HPβCD physical mixture (C) and NC : HPβCD (D) spray-dried system.
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Figure 4. DSC thermograms of NC (A), TAβCD (B), NC : TAβCD physical mixture (C) and NC : TAβCD (D) spray-dried system.
Figure 5. X-ray diffractograms of NC (A), HPβCD (B), NC : HPβCD physical mixture (C) and NC : HPβCD spray-dried system (D), TAβCD (E),
NC : TAβCD physical mixture (F) and NC : TAβCD spray-dried system (G).
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Figure 6. Dissolution profiles of NC and NC : HPβCD and NC : TAβCD systems at pH 1.2.
Figure 7. Dissolution profiles of NC and NC : HPβCD and NC : TAβCD systems at pH 6.8.
Figure 8. Dissolution profiles of (NC : HPβCD complex): (NC : TAβCD complex) in different molar ratios at pH 1.2.
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Figure 9. Dissolution profiles of (NC : HPβCD complex): (NC : TAβCD complex) in different molar ratios at pH 6.8.
significantly improved by complexation with HPβCD, spe-
cially in alkaline medium. In contrast, the drug release rate
from the NC : TAβCD spray-dried complex was markedly
retarded in both media.
An optimisation of the release profile of NC was fur-
ther attempted by changing the mixing ratio of each com-
plex in the formulation. The release profiles of NC from
formulations consisting of mixtures of NC : HPβCD and
NC : TAβCD complexes in various molar ratios, at pH 1.2
and pH 6.8 are presented in Figures 8 and 9, respectively.
The drug release from the different formulations oc-
curred in two stages: faster release in the initial stage (up to 1
hour) and slower release in the second stage. It is evident that
TAβCD retarded the drug release rate, being this retarding
effect dependent on the amount of hydrophobic complex in
the formulation. On the other hand, the initial release rate of
the drug increased with increasing amount of the hydrophilic
complex. Among the various combinations, we selected the
1 : 4 formulation to further in vivo studies in rabbits.
From the above reported data it was mainly concluded
that the drug release could be arbitrarily controlled by the
combination of hydrophilic and hydrophobic complexes in
an appropriate molar ratio.
References
1. J. Moyano, J. Gines, M. Arias, and A. Rabasco: Pharm. Acta Helv.
69, 81 (1994).
2. S. Badawy, A. Marshall, M. Ghorab, and M. Adeyeye: Drug Dev. Ind.
Pharm. 22, 959 (1996).
3. C. Ventura, G. Puglisi, M. Zappalà, and G. Mazzone: Int. J. Pharm.
160, 163 (1998).
4. F. Hirayama, M. Yamasaka, T. Horikawa, and K. Uekama: Chem.
Pharm. Bull. 43, 130 (1995).
5. V. Lemesle-Lamache, D. Wouessidjewe, M. Chéron, and D. Duchêne:
Int. J. Pharm. 141, 117 (1996).
6. Y. Ikeda, K. Kimura, F. Hirayama, H. Arima, and K. Uekama: J.
Control. Release 66, 271 (2000).
7. E. Sorkin and S. Clissold: Drugs 33, 296 (1987).
8. P. Job: Ann. Chim. 9, 113 (1925).
9. C.M. Fernandes, M.T. Vieira, and F.J.B. Veiga: Eur. J. Pharm. Sci. 15,
79 (2002).
10. C.A. Ventura, S. Tirendi, G. Puglisi, E. Bousquet, and L. Panza: Int.
J. Pharm. 149, 1 (1997).
11. S. Lin and Y. Kao: Int. J. Pharm. 56, 249 (1989).
12. J. Moyano, J. Ginés, M. Arias, and A. Rabasco: Int. J. Pharm. 114,
95 (1995).

